Rapid Generation of In-House Serological Assays Is Comparable to Commercial Kits Critical for Early Response to Pandemics: A Case With SARS-CoV-2.

Auerswald H, Eng C, Lay S, In S, Eng S, Vo HTM, Sith C, Cheng S, Delvallez G, Mich V, Meng N, Sovann L, Sidonn K, Vanhomwegen J, Cantaert T, Dussart P, Duong V, Karlsson EA

Open source

DOI: 10.3389/fmed.2022.864972
Published: 2022
Container: Frontiers in medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fmed.2022.864972,
  title = {Rapid Generation of In-House Serological Assays Is Comparable to Commercial Kits Critical for Early Response to Pandemics: A Case With SARS-CoV-2.},
  author = {Auerswald H and Eng C and Lay S and In S and Eng S and Vo HTM and Sith C and Cheng S and Delvallez G and Mich V and Meng N and Sovann L and Sidonn K and Vanhomwegen J and Cantaert T and Dussart P and Duong V and Karlsson EA},
  year = {2022},
  journal = {Frontiers in medicine},
  doi = {10.3389/fmed.2022.864972},
  url = {https://doi.org/10.3389/fmed.2022.864972}
}

RIS

TY  - JOUR
TI  - Rapid Generation of In-House Serological Assays Is Comparable to Commercial Kits Critical for Early Response to Pandemics: A Case With SARS-CoV-2.
AU  - Auerswald H
AU  - Eng C
AU  - Lay S
AU  - In S
AU  - Eng S
AU  - Vo HTM
AU  - Sith C
AU  - Cheng S
AU  - Delvallez G
AU  - Mich V
AU  - Meng N
AU  - Sovann L
AU  - Sidonn K
AU  - Vanhomwegen J
AU  - Cantaert T
AU  - Dussart P
AU  - Duong V
AU  - Karlsson EA
PY  - 2022
JO  - Frontiers in medicine
DO  - 10.3389/fmed.2022.864972
UR  - https://doi.org/10.3389/fmed.2022.864972
ER  -

APA

H, A., C, E., S, L., S, I., S, E., HTM, V., C, S., S, C., G, D., V, M., N, M., L, S., K, S., J, V., T, C., P, D., V, D., & EA, K. (2022). Rapid Generation of In-House Serological Assays Is Comparable to Commercial Kits Critical for Early Response to Pandemics: A Case With SARS-CoV-2.. Frontiers in medicine. https://doi.org/10.3389/fmed.2022.864972

Source records

pubmed · retrieved 2026-09-25T20:54:22.334Z